Consensus projects Johnson & Johnson's EPS CAGR of 8.9% (2026–2030), with forward P/E compressing from 20.8x to 14.8x. Read ...

The drugmaker and medical technology company sold its remaining shares in two previous partners.

Johnson & Johnson failed for years to resolve its talc liabilities in chapter 11, but is now gaining ground outside of ...

Royalty Pharma has inked a $500 million research-and-development co-funding agreement with Johnson & Johnson to support development of a proposed drug for autoimmune diseases.

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her ...

This stock is one to own during any market environment.

Johnson & Johnson on Wednesday announced plans to invest more than $1 billion in a next-generation manufacturing facility that will produce advanced cell therapy technologies. The facility will be ...

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor ...

Johnson & Johnson has teamed up with Naomi Watts to put a clearer focus on vision health, leveraging the actor’s star power to encourage women over 40 to make eye exams part of their self-care ...

A Los Angeles jury awarded $40 million on Friday to two women who claimed that talcum powder made by Johnson & Johnson caused their ovarian cancer. The giant health care company said it would appeal ...